242 related articles for article (PubMed ID: 17401217)
41. Clinical impact of MUC1 and MUC4 expression in Barrett-associated oesophageal adenocarcinoma.
Piessen G; Wacrenier A; Briez N; Triboulet JP; Van Seuningen I; Mariette C
J Clin Pathol; 2009 Dec; 62(12):1144-6. PubMed ID: 19946103
[TBL] [Abstract][Full Text] [Related]
42. Mucins MUC1, MUC2, MUC5AC and MUC6 expression in the evaluation of differentiation and clinico-biological behaviour of gastric carcinoma.
Pinto-de-Sousa J; David L; Reis CA; Gomes R; Silva L; Pimenta A
Virchows Arch; 2002 Mar; 440(3):304-10. PubMed ID: 11889602
[TBL] [Abstract][Full Text] [Related]
43. Expression of mucins (MUC1, MUC2, MUC5AC and MUC6) in mucinous carcinoma of the breast: comparison with invasive ductal carcinoma.
Matsukita S; Nomoto M; Kitajima S; Tanaka S; Goto M; Irimura T; Kim YS; Sato E; Yonezawa S
Histopathology; 2003 Jan; 42(1):26-36. PubMed ID: 12493022
[TBL] [Abstract][Full Text] [Related]
44. Is Barrett's esophagus the precursor of most adenocarcinomas of the esophagus and cardia? A biochemical study.
Mendes de Almeida JC; Chaves P; Pereira AD; Altorki NK
Ann Surg; 1997 Dec; 226(6):725-33; discussion 733-5. PubMed ID: 9409571
[TBL] [Abstract][Full Text] [Related]
45. Activation of Wnt signalling promotes development of dysplasia in Barrett's oesophagus.
Moyes LH; McEwan H; Radulescu S; Pawlikowski J; Lamm CG; Nixon C; Sansom OJ; Going JJ; Fullarton GM; Adams PD
J Pathol; 2012 Sep; 228(1):99-112. PubMed ID: 22653845
[TBL] [Abstract][Full Text] [Related]
46. Human fetal ductal plate revisited: II. MUC1, MUC5AC, and MUC6 are expressed in human fetal ductal plate and MUC1 is expressed also in remodeling ductal plate, remodeled ductal plate and mature bile ducts of human fetal livers.
Terada T
Int J Clin Exp Pathol; 2013; 6(4):571-85. PubMed ID: 23573304
[TBL] [Abstract][Full Text] [Related]
47. Mucin histochemistry of intestinal metaplasia in Barrett's esophagus.
Jauregui HO; Davessar K; Hale JH; Kessimian N; Cenoz C
Mod Pathol; 1988 May; 1(3):188-92. PubMed ID: 3237699
[TBL] [Abstract][Full Text] [Related]
48. Pericentriolar material analyses in normal esophageal mucosa, Barrett's metaplasia and adenocarcinoma.
Segat D; Cassaro M; Dazzo E; Cavallini L; Romualdi C; Salvador R; Vitale MP; Vitiello L; Fassan M; Rugge M; Zaninotto G; Ancona E; Baroni MD
Histol Histopathol; 2010 May; 25(5):551-60. PubMed ID: 20238294
[TBL] [Abstract][Full Text] [Related]
49. Immunohistochemical mucin expression of short-segment Barrett's esophagus.
Yamamoto S; Kijima H; Hara T; Kenmochi T; Kise Y; Tanaka H; Chino O; Shimada H; Tanaka M; Inokuchi S; Makuuchi H
Tokai J Exp Clin Med; 2003 Jul; 28(2):57-63. PubMed ID: 14714830
[TBL] [Abstract][Full Text] [Related]
50. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.
Villanacci V; Rossi E; Zambelli C; Galletti A; Cestari R; Missale G; Casa DD; Bassotti G
Dig Liver Dis; 2007 Apr; 39(4):305-11. PubMed ID: 17307036
[TBL] [Abstract][Full Text] [Related]
51. Esophageal polypoid dysplasia of gastric foveolar phenotype with focal intramucosal carcinoma associated with Barrett's esophagus.
Asthana N; Mandich D; Ligato S
Am J Surg Pathol; 2008 Oct; 32(10):1581-5. PubMed ID: 18724240
[TBL] [Abstract][Full Text] [Related]
52. Dynamics of SOX2 and CDX2 Expression in Barrett's Mucosa.
Barros R; Pereira D; Callé C; Camilo V; Cunha AI; David L; Almeida R; Dias-Pereira A; Chaves P
Dis Markers; 2016; 2016():1532791. PubMed ID: 27766003
[TBL] [Abstract][Full Text] [Related]
53. Hepatocyte antigen as a marker of intestinal metaplasia.
Chu PG; Jiang Z; Weiss LM
Am J Surg Pathol; 2003 Jul; 27(7):952-9. PubMed ID: 12826887
[TBL] [Abstract][Full Text] [Related]
54. [Expression and clinical significance of Mucin and E-cadherin in colorectal tumors].
Yu XW; Rong W; Xu FL; Xu GY; Sun YR; Feng MY
Ai Zheng; 2007 Nov; 26(11):1204-10. PubMed ID: 17991319
[TBL] [Abstract][Full Text] [Related]
55. Carbonic anhydrases II, IX, and XII in Barrett's esophagus and adenocarcinoma.
Nortunen M; Huhta H; Helminen O; Parkkila S; Kauppila JH; Karttunen TJ; Saarnio J
Virchows Arch; 2018 Nov; 473(5):567-575. PubMed ID: 30066203
[TBL] [Abstract][Full Text] [Related]
56. The diagnosis and management of Barrett's esophagus.
DeMeester SR; DeMeester TR
Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
[TBL] [Abstract][Full Text] [Related]
57. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.
Whitson MJ; Falk GW
Gastroenterol Clin North Am; 2015 Jun; 44(2):299-315. PubMed ID: 26021196
[TBL] [Abstract][Full Text] [Related]
58. Intestinal metaplasia of the stomach and esophagus: an immunohistochemical study of 60 cases including comparison with normal and inflamed intestinal mucosa.
Chlumská A; Mukenšnabl P; Mareček P; Zámečník M
Cesk Patol; 2014 Jul; 50(3):141-8. PubMed ID: 25186595
[TBL] [Abstract][Full Text] [Related]
59. Expression of CAS/CSE1L, the Cellular Apoptosis Susceptibility Protein, Correlates With Neoplastic Progression in Barrett's Esophagus.
Jiang K; Neill K; Cowden D; Klapman J; Eschrich S; Pimiento J; Malafa MP; Coppola D
Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):552-556. PubMed ID: 27941559
[TBL] [Abstract][Full Text] [Related]
60. Expression analysis of Barrett's esophagus-associated high-grade dysplasia in laser capture microdissected archival tissue.
Sabo E; Meitner PA; Tavares R; Corless CL; Lauwers GY; Moss SF; Resnick MB
Clin Cancer Res; 2008 Oct; 14(20):6440-8. PubMed ID: 18927283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
